Figure 2.
VentA overcomes aminoglycoside resistance in MDR clinical isolates. Checkerboard broth microdilution assays showing dose-dependent potentiation of aminoglycoside antibiotic by VentA. (A,B,C) Represent the ability of venturicidin A to potentiate gentamicin, kanamycin and amikacin respectively against MRSA C1014. (D,E,F) Represent the broad-spectrum activity of the combination against MDR isolates, MRSA C1024, EF C0558 and PA C0089, respectively. Dark regions represent higher cell density. For staphylococci and enterococci; the 100% growth corresponds to an OD600 of ~0.9 whereas for Pseudomonas it is ~0.4.